Compare VENUS REMEDIES with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES NATCO PHARMA VENUS REMEDIES/
NATCO PHARMA
 
P/E (TTM) x -13.9 34.8 - View Chart
P/BV x 0.9 4.9 18.7% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   NATCO PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
NATCO PHARMA
Mar-19
VENUS REMEDIES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs126849 14.8%   
Low Rs61557 11.0%   
Sales per share (Unadj.) Rs301.8573.8 52.6%  
Earnings per share (Unadj.) Rs-24.9176.0 -14.1%  
Cash flow per share (Unadj.) Rs2.5198.2 1.3%  
Dividends per share (Unadj.) Rs06.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs293.3842.7 34.8%  
Shares outstanding (eoy) m12.3436.50 33.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.31.2 25.3%   
Avg P/E ratio x-3.84.0 -94.1%  
P/CF ratio (eoy) x36.73.5 1,035.9%  
Price / Book Value ratio x0.30.8 38.2%  
Dividend payout %03.6 0.0%   
Avg Mkt Cap Rs m1,15425,660 4.5%   
No. of employees `0000.95.0 18.7%   
Total wages/salary Rs m3933,559 11.0%   
Avg. sales/employee Rs Th4,026.14,225.3 95.3%   
Avg. wages/employee Rs Th425.0718.0 59.2%   
Avg. net profit/employee Rs Th-331.81,295.9 -25.6%   
INCOME DATA
Net Sales Rs m3,72420,945 17.8%  
Other income Rs m231,302 1.7%   
Total revenues Rs m3,74722,247 16.8%   
Gross profit Rs m3957,948 5.0%  
Depreciation Rs m338810 41.8%   
Interest Rs m354193 183.6%   
Profit before tax Rs m-2758,247 -3.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m321,823 1.7%   
Profit after tax Rs m-3076,424 -4.8%  
Gross profit margin %10.637.9 27.9%  
Effective tax rate %-11.522.1 -51.9%   
Net profit margin %-8.230.7 -26.9%  
BALANCE SHEET DATA
Current assets Rs m2,63823,472 11.2%   
Current liabilities Rs m2,3057,287 31.6%   
Net working cap to sales %8.977.3 11.6%  
Current ratio x1.13.2 35.5%  
Inventory Days Days13592 146.9%  
Debtors Days Days4688 52.5%  
Net fixed assets Rs m4,87118,648 26.1%   
Share capital Rs m123365 33.8%   
"Free" reserves Rs m3,49634,525 10.1%   
Net worth Rs m3,61930,760 11.8%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50943,031 17.4%  
Interest coverage x0.243.7 0.5%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.5 101.9%   
Return on assets %0.615.4 4.1%  
Return on equity %-8.520.9 -40.6%  
Return on capital %1.627.4 5.8%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m011,536 0.0%   
Fx outflow Rs m5172,939 17.6%   
Net fx Rs m-5178,597 -6.0%   
CASH FLOW
From Operations Rs m5146,688 7.7%  
From Investments Rs m-123-6,122 2.0%  
From Financial Activity Rs m-387-509 76.1%  
Net Cashflow Rs m466 6.4%  

Share Holding

Indian Promoters % 32.9 52.0 63.1%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.2 7.8 2.3%  
FIIs % 0.6 16.6 3.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 26.0 255.4%  
Shareholders   20,121 25,395 79.2%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   WYETH  PIRAMAL ENTERPRISES  JUBILANT PHARMOVA   NEULAND LABS  IPCA LABS  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Apr 16, 2021 03:36 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS